TNF and rheumatoid arthritis: It has been shown that plasma miRNA signature of miRNA-23 and miRNA-223 was used as predictor and biomarker of response to anti-TNF-α/DMARDs combination therapy in RA patients (Castro-Villegas et al. 2015).